皮肤屏障功能障碍和金黄色葡萄球菌（金葡菌）定植是特应性皮炎发生发展的关键因素，金葡菌的清除以及皮肤正常共生菌调节的皮肤内环境稳态恢复是特应性皮炎治疗的核心。课题组在分别鉴定了对金葡菌有特异杀灭作用的噬菌体JD007以及对金葡菌有拮抗作用的皮肤共生益生菌SHoFu的基础上，在全基因组水平发现它们均不会作为有害基因传播的载体，SHoFu能维持与之直接接触的并在皮肤内环境稳态中起重要作用的皮肤角质细胞恒稳分泌胸腺基质淋巴细胞生成素（TSLP），显示了它们具有开发成微生态制剂的潜在价值。本课题拟利用特应性皮炎皮肤金葡菌定植模型，研究含有JD007和SHoFu的微生态制剂对金葡菌的去定植能力、在皮肤的定植周期和减轻皮肤炎症的效果，并阐明SHoFu维持皮肤内环境稳态的作用机理。本项目将为开发改善特应性皮炎的微生态制剂奠定重要理论基础。

Skin barrier obstacle and colonization by Staphylococcus aureus are the key factors for occurrence and deterioration of atopic dermatitis (AD). The clearance of S.aureus and recovery of dermal homeostasis by the normal commensal bacteria in skin are the cores for AD treatment. We previously identified a virulent bacteriophage JD007 and skin probiotic–Staphylococcus homonis SHoFu, both of them could inhibit the growth of S. aureus and would not be the vectors of horizontal transfer adverse genes; Furthermore, SHoFu could keep Keratinocyte cell stable secretion of TSLP that was interrupted by S. aureus, our previous study showed that both JD007 and SHoFu are potential for development of microbial agents for clinical therapy. This project will further study their colonization periods in skin, the efficacy of decolonization S. aureus in AD skins and improvement for AD treatment in mice model. Furthermore, the mechanism of SHoFu for keeping skin homeostasis will be elucidated. This project will make the theoretical foundation in developing novel microbial agents for treating AD.